Esophageal adenocarcinoma · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
ECF/5-FU and RT Variant #01 | — | R 5 014 | 63d | — | — | — | — | — |
FULV and RT Variant #07 | — | R 1 616 | 70d | — | 36.0 mo | — | — | 1 |
Cisplatin and Irinotecan (IC) N/A - secondary systemic drug | — | R 743 | 42d | ~3.8 mo | ~13.9 mo | ~3 | ~R 2 230 PFS proxy · indirect | 2 |
Cisplatin and Paclitaxel (TP) Variant #01 | — | R 716 | 10d | ~5.6 mo | ~11.1 mo | ~18 | ~R 12 892 PFS proxy · indirect | 8 |
Observation Partial | — | — | — | ~3.4 mo | ~36.1 mo | — | — | 18 |
5 of 5 regimens shown